Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 42%, Even After 5.3% Gain This Past Week
Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 42%, Even After 5.3% Gain This Past Week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) shareholders for doubting their decision to hold, with the stock down 42% over a half decade. But it's up 5.3% in the last week. Less than a week ago Shenzhen Neptunus Bioengineering announced its financial results; you can catch up on the most recent data by reading our company report.
为了证明挑选个股的努力是合理的,值得努力超越市场指数基金的回报。但几乎可以肯定的是,每个投资者都会同时拥有表现优异和表现不佳的股票。所以我们不会责怪长期深圳市海王星生物工程有限公司。(SZSE:000078)股东对他们持有股票的决定表示怀疑,该股在过去五年中下跌了42%。但最近一周上涨了5.3%。不到一周前,深圳海王星生物工程公司公布了财务业绩;您可以通过阅读我们的公司报告来了解最新的数据。
Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline.
尽管过去一周对股东来说更令人安心,但他们在过去五年仍处于亏损状态,所以让我们看看基础业务是否对股价下跌负有责任。
View our latest analysis for Shenzhen Neptunus Bioengineering
查看我们对深圳海王星生物工程的最新分析
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
在他的文章中格雷厄姆和多德斯维尔的超级投资者沃伦·巴菲特描述了股价并不总是理性地反映一家企业的价值。一种不完美但简单的方法来考虑市场对一家公司的看法是如何改变的,那就是将每股收益(EPS)的变化与股价走势进行比较。
In the last half decade Shenzhen Neptunus Bioengineering saw its share price fall as its EPS declined below zero. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
在过去的五年里,深圳海王星生物工程的股价下跌,每股收益降至零以下。由于该公司已陷入亏损状态,很难将每股收益的变化与股价的变化进行比较。然而,我们可以说,在这种情况下,我们预计会看到股价下跌。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS是如何随着时间的推移进行跟踪的(如果您点击该图像,您可以看到更多详细信息)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/pic/0-b47f91155630b8ee116c6228cda58447-0-3b3accbf790cba07b2eef4f3edcf0360.png/big)
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在买卖股票之前,我们总是建议仔细研究一下历史增长趋势,可以在这里找到。
A Different Perspective
不同的视角
Shenzhen Neptunus Bioengineering shareholders gained a total return of 5.0% during the year. But that return falls short of the market. On the bright side, that's still a gain, and it is certainly better than the yearly loss of about 7% endured over half a decade. It could well be that the business is stabilizing. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Shenzhen Neptunus Bioengineering is showing 2 warning signs in our investment analysis , you should know about...
深圳海王星生物工程股东年内总回报达5.0%。但这一回报率低于市场。从好的方面来看,这仍然是一种收益,而且肯定比五年来每年约7%的损失要好。这很可能是因为业务正在企稳。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。即便如此,请注意深圳海王星生物工程公司正在展示我们的投资分析中的2个警告信号,你应该知道关于……
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
如果你喜欢和管理层一起买股票,那么你可能会喜欢这本书免费公司名单。(提示:内部人士一直在买入这些股票)。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。